Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push
08:32am, Wednesday, 15'th Oct 2025
Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disord
Meet the 1.4% Yield Dividend Stock That Could Soar in 2026
04:00am, Wednesday, 15'th Oct 2025
Danish pharmaceutical giant Novo Nordisk (NVO -1.47%) has endured a significant decline in stock price, falling over 50% in the past year. The stock's miserable performance is particularly jarring, co
Focus: Inside Novo Nordisk's 'Club 5,000' as Danish staff cuts gain pace
02:06am, Wednesday, 15'th Oct 2025
Romel Amineh is one of a fast-growing group of Novo Nordisk workers in Denmark laid off as the drugmaker battles to cut costs and revive its fortunes in a fiercely competitive global obesity drug mark
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:00am, Tuesday, 14'th Oct 2025
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Smartest Growth Stock to Buy With $100 Right Now
07:23am, Monday, 13'th Oct 2025
One of the great things about equity markets is that excellent stocks can be had at almost any price, making them accessible to most people. Even with $100, it's possible to find outstanding, growth-o
3 Top Healthcare Stocks to Buy in October
05:21am, Monday, 13'th Oct 2025
Healthcare stocks have lagged the broader stock market over the past year. Political tensions following the slaying of an insurance executive and policy uncertainty following the transition to the Tru
Should You Buy Novo Nordisk Right Now?
09:43am, Sunday, 12'th Oct 2025
Wall Street analysts can't agree on Novo Nordisk (NVO -2.96%), with Morgan Stanley recently cutting its rating to underweight on the back of disappointing growth in key prescriptions in the U.S., and
Evening digest: Israel-Hamas ceasefire, India-UK missile deal, Novo Nordisk’s big acquisition
01:30pm, Friday, 10'th Oct 2025
Thursday evening's digest came with big moves and major updates from around the world. Israel and Hamas have agreed to a ceasefire, India and the UK are teaming up on a massive missile deal, Google is
Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition
01:30pm, Friday, 10'th Oct 2025
Novo Nordisk said on Thursday it would acquire Akero Therapeutics for up to $5.2 billion in cash, marking a significant push into treatments for fatty liver disease as the Danish drugmaker seeks to br
Novo Nordisk halts work on cell therapy for diabetes to cut costs, Bloomberg News reports
11:55am, Friday, 10'th Oct 2025
Novo Nordisk has cut its cell therapy division, which has been trying to find a cure for type 1 diabetes, Bloomberg News reported on Friday, citing a statement.
Can Novo Nordisk's Aggressive Deal-Making Offset Semaglutide Reliance?
10:55am, Friday, 10'th Oct 2025
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Is Novo Nordisk Stock a Sell Despite its 10% Price Rally in a Month?
12:00pm, Thursday, 09'th Oct 2025
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
Eastover Opens a Brand New $3.3 Million Novo Nordisk Position
11:29am, Thursday, 09'th Oct 2025
Eastover Investment Advisors LLC initiated a new position in Novo Nordisk (NVO -1.29%), acquiring 59,811 shares during the quarter in an estimated $3.32 million trade, according to its October 7, 2025
Novo Nordisk A/S (NVO) M&A Call Transcript
10:26am, Thursday, 09'th Oct 2025
Novo Nordisk A/S (NVO) M&A Call October 9, 2025 8:00 AM EDT Company Participants Jacob Martin Rode - Head of Investor Relations Maziar Doustdar - President, CEO & Member of the Management Board Ludovi
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
10:21am, Thursday, 09'th Oct 2025
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's
